News - Infinity Pharmaceuticals


Current filters:

Infinity Pharmaceuticals

Popular Filters

Infinity regains global rights to PI3K, FAAH; equity investment by Purdue


USA-based Infinity Pharmaceuticals (Nasdaq: INFI) says it has restructured its strategic alliance with…

FinancialInfinity PharmaceuticalsLicensingMundipharmaPharmaceuticalPurdue PharmaResearch

Infinity plunges as it halts two saridegib trials


US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) saw its shares plummet 20% to $11 in pre-marketing…

Infinity PharmaceuticalsIPI-145MundipharmaOncologyPharmaceuticalResearchretaspimycinsaridegib

Mundipharma commits over $50 million in R&D funding for Infinity’s PI3K inhibitor


Privately-held Mundipharma International as committed to providing over $50 million in funding in 2013…

FinancialInfinity PharmaceuticalsInflammatory diseasesLicensingMundi InternationalOncologyPharmaceuticalResearch

Back to top